Portable mass spectrometric detection system for genotoxic impurities
Through a portable mass spectrometry detection system, combined with thermal analysis chamber, ionization chamber and mass spectrometer, the problem of genotoxic impurity detection equipment in the prior art is not portable and fast detection, and the on-site detection capability is improved and operation is simplified, and the cost is reduced. .
Patent Information
- Application Number
- CN202420188673.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-25
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2034-01-25
AI Technical Summary
The existing genotoxic impurity detection equipment cannot achieve portable and fast on-site detection, and is complex in operation, time-consuming and costly, and cannot meet the on-site detection needs.
A portable mass spectrometry detection system was designed, including a thermal analytical cavity, an ionization cavity and a mass spectrometer. The gasified sample is heated through the thermal analytical cavity, and the ionization cavity is ionized to form charged ions. The mass spectrometer detects charged ions, which simplifies the operation steps and realizes the field. Test.
It realizes on-site detection of genotoxic impurities, has strong detection capabilities, can accurately detect under interference from drug matrix, significantly reduces the volume, simplifies operation, and reduces costs.
Smart Images

Figure CN221945915U_ABST
Abstract
Description
Technical Field
[0001] The utility model relates to the field of drug detection, in particular to a portable mass spectrometry detection system for genotoxic impurities. Background Art
[0002] Genotoxic impurities (GTI) refer to a class of impurities in drugs that can directly or indirectly cause DNA damage and cause gene mutations, and are carcinogenic or potentially carcinogenic. The residues of genotoxic impurities in drugs are increasingly receiving attention. Since the detection of N-nitrosodimethylamine (NDMA) in valsartan APIs in July 2018, various types of nitrosamine impurities, such as NDMA and N-nitrosodiethylamine (NDEA), have been detected in other sartan APIs. Nitrosamine impurities belong to the "concern queue" substances mentioned in the ICH M7 (R1) (Evaluation and Control of DNA Reactive (Mutagenic) Impurities in Drugs to Limit Potential Carcinogenic Risk) guidelines. According to the list of carcinogens published by the World Health Organization, NDMA and NDEA are both Class 2A carcinogens; currently, some nitrosamine impurities have public carcinogenicity data, such as NDMA, NDEA, N-nitroso-N-methyl-4-aminobutyric acid (NMBA), N-nitrosodibutylamine (NDBA), etc. This type of genotoxic impurity is present in low concentrations in drugs, and the drug matrix is extremely complex, requiring high sensitivity in the detection instrument.
[0003] At present, the detection methods for samples containing genotoxic impurities include liquid chromatography-mass spectrometry, gas chromatography-mass spectrometry and other methods. These methods are sent to professional laboratories for detection and analysis using large-scale precision equipment. After the samples undergo complex pre-treatment, liquid chromatography or gas chromatography is used to separate the samples, and then detectors are used for detection. These devices are not only time-consuming and costly, but also have high requirements on the technical ability of the operator. They can only be performed in professional laboratories and cannot meet the requirements of rapid on-site detection. Utility Model Content
[0004] The utility model aims to provide a portable mass spectrometry detection system for genotoxic impurities, so as to solve the problem that the existing detection equipment can only be used in laboratories and cannot achieve portable and rapid on-site detection.
[0005] The above purpose can be achieved through the following technical solutions:
[0006] A portable mass spectrometry detection system for genotoxic impurities, comprising:
[0007] A thermal analysis chamber, used for heating and vaporizing samples, wherein the thermal analysis chamber is provided with a test paper inlet and a carrier gas inlet;
[0008] An ionization chamber is used to ionize the gasified sample to form charged ions, and the ionization chamber is connected to the thermal desorption chamber through a carrier gas pipeline;
[0009] The mass spectrometer is used to detect the charged ions generated in the ionization chamber, and the mass spectrometer is connected to the ionization chamber through an ion transmission pipeline.
[0010] Optionally, the portable mass spectrometry detection system for genotoxic impurities further comprises:
[0011] Sample test paper, used to send samples into the thermal desorption chamber.
[0012] The sample test paper is inserted into the test paper inlet to deliver the sample into the thermal analysis chamber.
[0013] Optionally, the mass spectrometer is a portable ion trap mass spectrometer.
[0014] Optionally, a valve is provided on the ion transfer pipeline.
[0015] Optionally, an atmospheric pressure chemical ionization source is provided in the ionization chamber.
[0016] Optionally, the atmospheric pressure chemical ionization source forms an electric field in the ionization chamber that causes charged ions to flow toward the mass spectrometer.
[0017] Optionally, a heating device is provided in the thermal analysis chamber for heating and vaporizing the sample on the test paper carrying the sample.
[0018] Optionally, the heating device is an electric heating plate or an electric heating rod.
[0019] Optionally, the heating device is a variable temperature heating device.
[0020] Optionally, a pipeline connecting the carrier gas inlet and the carrier gas pipeline is provided in the thermal analysis chamber, and the sample heated and vaporized in the thermal analysis chamber enters the pipeline and enters the ionization chamber along with the carrier gas.
[0021] The utility model has the following beneficial effects:
[0022] The utility model adopts a combination of a thermal desorption chamber, an ionization chamber and a mass spectrometer, which significantly reduces the size of the detection instrument and can realize on-site detection of genotoxic impurities. The detection system only needs to use a pipette to absorb the quantitative sample onto the test paper and send it into the injector, without the need for the previous chromatographic column operation, which greatly simplifies the operation steps. Not only can it directly detect genotoxic impurity standard samples, but it can also detect genotoxic impurities under the interference of drug matrix, and has strong detection ability. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] In order to more clearly illustrate the specific implementation methods of the utility model or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the utility model. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0024] Figure 1 Schematic diagram of the detection system structure; markings in the figure: 1. thermal desorption chamber, 2. ionization chamber, 3. mass spectrometer, 4. test paper, 11. carrier gas inlet, 12. carrier gas pipeline, 21. ion transmission pipeline;
[0025] Figure 2 It is the fitting curve obtained by testing the NDMA reference solution using methanol as the dilution solvent;
[0026] Figure 3 It is the fitting curve obtained by testing the NDMA reference solution using dichloroethane as the dilution solvent;
[0027] Figure 4 is the fitting curve obtained by testing the NDEA reference solution using methanol as the dilution solvent;
[0028] Figure 5 is the fitting curve obtained by testing the NDEA reference solution using dichloroethane as the dilution solvent;
[0029] Figure 6 This is the NDMA parent ion spectrum;
[0030] Figure 7 It is the fragment ion spectrum of NDMA;
[0031] Figure 8 is the NDEA precursor ion spectrum;
[0032] Fig. 9 is the fragment ion spectrum of NDEA;
[0033] Fig.10 is the NDEA parent ion spectrum in Experimental Example 2;
[0034] Fig.11 This is the NDMA parent ion spectrum in Experimental Example 2. DETAILED DESCRIPTION
[0035] Now, various exemplary embodiments of the present invention are described in detail. This detailed description should not be considered as a limitation of the present invention, but should be understood as a more detailed description of certain aspects, characteristics and embodiments of the present invention. It should be understood that the terms described in the present invention are only used to describe specific embodiments and are not used to limit the present invention.
[0036] Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art in the field of the utility model. Although the utility model only describes preferred methods and materials, any methods and materials similar or equivalent to those described herein can also be used in the implementation or testing of the utility model.
[0037] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0038] Example 1
[0039] like Figure 1 A portable mass spectrometry detection system for genotoxic impurities shown includes: a thermal desorption chamber 1, an ionization chamber 2 and a mass spectrometer 3.
[0040] The thermal analysis chamber 1 is provided with a test paper inlet for inserting the test paper 4 and a carrier gas inlet 11 for introducing the carrier gas; a heating device is provided in the thermal analysis chamber for heating and vaporizing the sample on the test paper with the sample. The heating device can be a constant temperature heater or a variable temperature heater, preferably a variable temperature heater. The heating device can be a heating plate or an electric heating rod. The thermal analysis chamber is provided with a pipeline connecting the carrier gas inlet and the carrier gas pipeline, and the sample heated and vaporized by the thermal analysis chamber enters the pipeline and enters the ionization chamber with the carrier gas.
[0041] An atmospheric pressure chemical ionization source is provided in the ionization chamber 2 for ionizing the vaporized sample to form charged ions, and the ionization chamber is connected to the thermal desorption chamber through a carrier gas pipeline 12. The atmospheric pressure chemical ionization source forms an electric field in the ionization chamber to make the charged ions flow toward the mass spectrometer.
[0042] The mass spectrometer 3 is used to detect the charged ions generated in the ionization chamber, and the mass spectrometer is a portable ion trap mass spectrometer. The mass spectrometer 3 is connected to the ionization chamber 2 through an ion transmission pipeline 21, and a valve is provided on the ion transmission pipeline.
[0043] The steps for testing using this system include:
[0044] 1. Sample pretreatment: ① Reference sample: dilute the standard sample to obtain the required concentration; ② Test sample: crush the test sample and dissolve it with a solvent to obtain a turbid liquid, then let it stand, and take the supernatant as the test sample; the liquid sample pretreatment method is the same as the standard sample, and the solvent is directly diluted. The solvent used for dilution: can be methanol or dichloromethane. The test sample can be an actual drug, or a drug intermediate or preparation.
[0045] 2. Injection: Use a pipette to absorb a quantitative amount of pre-treated liquid sample onto the test paper, and insert the test paper directly into the test paper injection port of the thermal desorption chamber to complete the sample injection.
[0046] 3. Detection: When the test paper containing the test sample is inserted into the test paper inlet of the thermal desorption chamber, the heating device raises the temperature in the chamber to 50-300°C. When the temperature in the chamber is higher than the melting and boiling points of the sample, the sample on the test paper is vaporized to form sample gas, which is ionized as the carrier gas reaches the ionization zone. The sample gas is ionized in the ionization chamber to form charged ions, and then the valve is opened. The charged sample ions enter the cavity of the mass spectrometer under the dual effects of gas pressure and electric field, and then the target ions are ejected from the trap through the ion trap selection. The detector amplifies the signal of the ejected ions to achieve target ion detection.
[0047] The heating temperature of the thermal analysis chamber can be either constant, such as maintaining it at around 200°C to vaporize the sample; or it can be a variable temperature injector. The injector temperature is first maintained at a slightly lower temperature to volatilize a portion of the sample, and then the injector temperature is increased to volatilize the sample with a high melting and boiling point, thereby achieving preliminary separation of the mixed sample at the injection stage.
[0048] Test Example 1
[0049] The genotoxic impurity reference samples were tested using a portable mass spectrometry detection system for genotoxic impurities.
[0050] ①Sample configuration:
[0051] Preparation of NDMA reference sample solution: NDMA sample (concentration 99.0%) was diluted step by step using dichloromethane / methanol.
[0052] Preparation of NDEA reference sample solution: NDEA sample (concentration 99.0%) was diluted serially using dichloromethane / methanol.
[0053] ②Detection:
[0054] Thermal desorption temperature 200℃, atmospheric pressure chemical ion source, small ion trap mass spectrometer.
[0055] Linear detection: Use dichloromethane / methanol to dilute NDMA samples to prepare five concentrations of sample solutions: 0.1ng / μL, 0.2ng / μL, 0.5ng / μL, 1ng / μL, and 1.5ng / μL; use methanol to dilute NDEA samples to prepare five concentrations of sample solutions: 1ng / mL, 2ng / mL, 5ng / mL, 10ng / mL, and 20ng / mL; use dichloromethane to dilute NDEA samples to prepare five concentrations of sample solutions: 1ng / mL, 2ng / mL, 5ng / mL, 10ng / mL, and 15ng / mL;
[0056] Detection limit test: Use methanol solution to dilute the reference solution step by step, such as Figures 2 to 5 As shown in the figure, the minimum detection limits of two genotoxic impurities, NDMA and NDEA, were finally obtained using a portable mass spectrometer, which were 0.21ng / μL (NDMA) and 0.931pg / μL (NDEA), respectively. The unique cascade function of the ion trap mass spectrometer was used to perform secondary processing on the parent ions to obtain the sample fragment peak information for further confirmation of the detected samples. The test spectra are shown in the figure below. Figures 6 to 9 As shown in Table 1.
[0057] Table 1
[0058] sample Precursor ion peak position Secondary fragment peak position Minimum detection concentration NDMA 75.1 44、57.9 0.21ppm NDEA 103.1 75 0.931ppb
[0059] Test Example 2
[0060] A portable mass spectrometry detection system for genotoxic impurities was used to detect genotoxic impurity sample solutions based on drugs.
[0061] ①Matrix solution configuration:
[0062] Three losartan potassium tablets (50 mg / tablet) were crushed and ultrasonically dissolved in 1 mL of dichloromethane to obtain a turbid solution, which was centrifuged and the supernatant was taken as the drug matrix solution.
[0063] ②Test sample configuration:
[0064] NDMA matrix standard preparation: Transfer the NDMA reference solution to the sample matrix solution to a final concentration of 0.5 ng / μL.
[0065] NDEA matrix standard preparation: transfer NDEA reference solution to sample matrix solution, and the final preparation concentration is 0.1 ng / μL.
[0066] ③Detection:
[0067] Thermal desorption temperature is 200℃, atmospheric pressure chemical ion source, small ion trap mass spectrometer. The substance library is established based on the peak position obtained from the NDMA and NDEA reference solution test, and the drug matrix solution is first tested with this substance library. There are no alarm signals for the two genotoxic impurities NDMA and MDEA, and the test spectrum has no signal peaks. Subsequently, the genotoxic impurity sample solution with the drug as the matrix is tested, and 0.5ppmNDMA and 0.1ppmNDEA are accurately alarmed, such as Fig.10 , 11 As shown, the parent ion peak can be clearly seen in the test spectrum.
[0068] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. A portable mass spectrometry detection system for genotoxic impurities, characterized in that: include: A thermal analysis chamber, used for heating and vaporizing samples, wherein the thermal analysis chamber is provided with a test paper inlet and a carrier gas inlet; An ionization chamber is used to ionize the gasified sample to form charged ions, and the ionization chamber is connected to the thermal desorption chamber through a carrier gas pipeline; The mass spectrometer is used to detect the charged ions generated in the ionization chamber, and the mass spectrometer is connected to the ionization chamber through an ion transmission pipeline.
2. The portable mass spectrometry detection system for genotoxic impurities according to claim 1, characterized in that: The portable mass spectrometry detection system for genotoxic impurities also includes: Sample test paper, used to send samples into the thermal desorption chamber.
3. The portable mass spectrometry detection system for genotoxic impurities according to claim 1, characterized in that: The mass spectrometer is a portable ion trap mass spectrometer.
4. The portable mass spectrometry detection system for genotoxic impurities according to claim 1, characterized in that: The ion transmission pipeline is provided with a valve.
5. The portable mass spectrometry detection system for genotoxic impurities according to claim 1, characterized in that: An atmospheric pressure chemical ionization source is arranged in the ionization chamber.
6. The portable mass spectrometry detection system for genotoxic impurities according to claim 5, characterized in that: The atmospheric pressure chemical ionization source forms an electric field in the ionization chamber to make charged ions flow toward the mass spectrometer.
7. The portable mass spectrometry detection system for genotoxic impurities according to claim 1, characterized in that: A heating device is provided in the thermal analysis chamber for heating and vaporizing the sample on the test paper with the sample.
8. The portable mass spectrometry detection system for genotoxic impurities according to claim 7, characterized in that: The heating device is an electric heating plate or an electric heating rod.
9. The portable mass spectrometry detection system for genotoxic impurities according to claim 7, characterized in that: The heating device is a variable temperature heating device.
10. The portable mass spectrometry detection system for genotoxic impurities according to claim 1, characterized in that: A pipeline connecting the carrier gas inlet and the carrier gas pipeline is arranged in the thermal analysis chamber, and the sample heated and vaporized in the thermal analysis chamber enters the pipeline and enters the ionization chamber along with the carrier gas.
